🔴 Corcept Therapeutics is trading 4.5% down today — no specific bearish catalyst identified

Corcept Therapeutics is trading 4.5% down at $109.71 despite favorable developments; no reliable source identified a specific bearish catalyst.

• Biotechnology stocks gained 2.55% on September 18, 2026.
• Corcept announced a positive CHMP recommendation for European authorization of relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer.
• H.C. Wainwright reiterated its Buy rating and $165 target.